Cytori Reports Q1 2019 Business and Financial Results (GlobeNewswire, Cytori Therapeutics Inc.) - May 14, 2019 - ATI-0918, a generic version of pegylated liposomal doxorubicin hydrochloride, is the lead product candidate. The Company plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) next year based on a successful bioequivalence study completed against the European reference drug...Cytori is also developing ATI-1123, a patented, albumin-stabilized pegylated liposomal docetaxel.
European regulatory
|